This study characterized the prevalence and patterns of antiretroviral-drug-resistance mutations according to plasma human immunodeficiency virus type 1 (HIV-1) RNA load in a large population of patients with HIV-1 infection who underwent testing for resistance mutations in routine clinical practice. HIV-1 genotypic resistance test results with linked clinical data were obtained from national resistance and clinical databases in the United Kingdom. Among 7861 tests, detection of у1 resistance mutation was most frequent at viral loads of 300-10,000 copies/mL and decreased statistically significantly at viral loads of 110,000 copies/mL. Major resistance mutations were commonly detected in the subset of tests that were performed among patients with viral loads of !1000 copies/mL (1001 [12.7%] of 7861 tests). We conclude that HIV-1 genotypic resistance testing is informative for patients with low viral loads.
mount among patients with low-level viremia, to allow a timely and optimized therapeutic change.
Current HIV-1 genotypic resistance assays are validated for viral loads of 11000 copies/mL, which is the recommended optimal threshold for testing. Routine assays can, however, be adapted to perform well at lower levels of viremia, and many clinical centers routinely perform resistance tests for patients with viral loads of !1000 copies/mL, with high success rates [4, 5] . The aim of this study was to characterize the population of patients undergoing drug-resistance testing at viral loads of !1000 copies/mL, to describe the patients' HIV-1 genotypic resistance profiles, and to identify factors associated with the detection of resistance mutations according to viral load.
Methods. HIV-1 genotypic resistance test results were obtained from the UK HIV Drug Resistance Database (http:// www.hivrdb.org.uk) and linked to clinical data from the UK Collaborative HIV Cohort Study [6] . Patients who started antiretroviral therapy during the period 1999-2006, whose drug resistance was tested after the start of therapy, and whose viral load was measured within 2 weeks before to 4 weeks after the date of the resistance test were eligible. If patients had 11 resistance test performed after starting therapy, all test results were included. Major resistance mutations were identified according to the International AIDS Society-USA list [7] .
We analyzed the relationship between viral load at the time of the resistance test and the probability of detection of resistance mutations, with focus on tests performed at low viral load (defined as !1000 copies/mL). For those assays performed at low viral load, the majority (856 [86%] of 1001) came from 3 clinical centers where either the VircoType test (Virco) or inhouse methods including a nested polymerase chain reaction step were used. The sequencing success rates in these 3 centers were 70% for the VircoType test [8] and 85%-92% for the inhouse methods [N.E. Mackie and A.M. Geretti, unpublished data]. Failure of a drug was defined by a viral load of 1400 copies/mL after 14 months of continuous use of the drug, an intentionally broad definition aimed at capturing all possible virologic failures. Generalized linear models with log link and Poisson errors (using generalized estimating equations) were used to assess multivariable (adjusted) relative risks (RRs) for the association between covariates and risk of a mutation being present [9] . The same approach was used to analyze the detection of resistance to any class of antiretroviral drug and the detections of class-specific drug resistance among patients who received regimens that contained nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and patients who received reg- NOTE. The P value refers to a x 2 test comparing patients who had viral loads of 11000 copies/mL with patients who had viral loads of !1000 copies/mL. HAART, highly active antiretroviral therapy; NNRTI, nonnucleoside reversetranscriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; PI-r, ritonavir-boosted PI.
imens that contained protease inhibitors (PIs). All analyses were also repeated, excluding those patients who were not receiving antiretroviral therapy at the time that they were tested for drug resistance and those patients whose viral load was measured before or after the resistance test was performed.
Results. Table 1) .
The overall prevalence of resistance (ie, the number of tests that detected at least 1 major drug-resistance mutation to any drug class) fell markedly over time, from a peak of 75% in 1999 to 48% in 2006. The prevalence of NRTI resistance mutations closely mirrored the overall trend (from 73% in 1999 to 43% in 2006), whereas the prevalence of NNRTI resistance mutations increased from 68% in 1999 to 76% in 2003 and subsequently decreased to 56%. The most striking change was observed for PI resistance mutations, with prevalence decreasing by ∼50% from 52% in 1999 to 24% in 2006. Independent predictors of the detection of resistance included earlier year of testing ( ), use of NNRTI-containing regi-P ! .001 mens ( ), increasing numbers of previously failed drugs P ! .001 ( ), and never having achieved a viral load of !50 copies/ P ! .001 mL ( ); there was also a marginal increase in detections P ! .001 of resistance with time since starting antiretroviral therapy ( ). P p . 02 The prevalence of resistance mutations varied according to the viral load ( Table 2) . Detection of at least 1 resistance mutation, both overall and specific to 1 drug class, was most frequent among tests performed at viral loads of 300-10,000 copies/mL and decreased as the viral load increased above these levels. Although PI resistance mutations were less frequent overall than were NRTI or NNRTI resistance mutations, their prevalence was still greatest at viral loads of 300-10,000 copies/mL. Restricting the analyses to those patients whose viral load was measured on the same day that the resistance test was performed did not significantly change these results.
An analysis was performed to determine the total number of mutations detected according to viral load (data not shown). Overall, there was no convincing evidence of differences in the number of mutations detected according to viral load among those patients for whom at least 1 mutation was detected. The median number of mutations was 3 (IQR, 1-5), 4 (IQR, 2-6), 4 (IQR, 2-6), 4 (IQR, 2-6), 4 (IQR, 2-6), 3 (IQR, 2-6), and 3 (IQR, 1-6) at the viral load strata of !300, 300-999, 1000-2999, 3000-9999, 10,000-29,999, 30,000-99,999, and 1100,000 copies/mL, respectively ( ; global Kruskal-Wallis test for P p .009 differences).
Overall, 6136 tests were performed among patients who experienced NRTI failure. The thymidine analogue mutations were highly prevalent in this population, with M41L, D67N, and T215Y each detected in 120% of the tests, followed by K70R, L210W, T215F, and K219Q/E. The M184V mutation was detected in 39% of the tests, whereas K65R and L74V were detected in !10% of the tests. The prevalence of the thymidine analogue mutation 1 pathway mutations M41L, L210W, and T215Y was statistically significantly lower at low viral loads than the prevalence at higher viral loads ( for each), but P ! .001 other thymidine analogue mutations occurred at equal frequency below and above viral loads of 1000 copies/mL. There were also no statistically significant differences in the frequencies of M184V and K65R below and above viral loads of 1000 copies/mL. However, the M184V mutation was less common among patients receiving a ritonavir-boosted PI, compared with those receiving an NNRTI (RR, 0.63 [95% confidence interval {CI}, 0.47-0.85]) but not among patients receiving a single PI compared with those receiving an NNRTI (RR, 1.14 [95% CI, 0.86-1.50]). Although the L74V mutation was relatively uncommon, it was statistically significantly more prevalent at viral loads of 11000 copies/mL (6.5%) when compared with lower viral loads (3.3%; ). Among patients who experienced P ! .001 NNRTI failure ( ), the most common mutations were n p 1864 K103N, which was detected in 135% of the tests, followed by Y181C, G190A, and V108I, with no statistically significant differences according to viral load being observed. Of 2759 tests performed among patients who experienced PI failure, 66% of these tests were performed among patients receiving a ritonavirboosted PI. The PI mutations that occurred at the highest prevalence were L90M, M46I, V82A, and D30N; of these, I84V and L90M were less prevalent at viral loads of !1000 copies/mL than at higher viral loads ( for both ), whereas the other P ! .001 mutations showed similar frequencies below and above viral loads of 1000 copies/mL. The statistically significant differences were also observed when patients receiving ritonavir-boosted PI regimens were analyzed separately from the overall population with PI failure.
Discussion. There has been an increase in HIV-1 genotypic resistance testing at viral loads of !1000 copies/mL in the United Kingdom over recent years, from 3.4% of tests before 1999 to 21.9% of tests in 2006. To our knowledge, this paper provides the first substantive analysis of the prevalence of major resistance mutations at viral loads of !1000 copies/mL among patients accessing routine care and undergoing population sequencing of reverse transcriptase and protease.
Over 60% of all resistance tests detected evidence of resistance. In assessing the relationship between the prevalence of resistance and viral load, the highest rates of detection of resistance mutations were observed at viral loads of 300-10,000 copies/mL. Furthermore, several major resistance mutations were as likely to be detected at viral loads of !1000 copies/mL as they were to be detected at viral loads above this level. These resistance mutations included K65R, M184V, and pathway 2 thymidine analogue mutations; the NNRTI resistance mutations K103N, Y181C, and G190A; and the protease mutations D30N, M46I, and V82A. The increasing proportion of resistance tests conducted at viral loads of !1000 copies/mL is therefore unlikely to explain the observed overall decrease in the prevalence of antiretroviral drug resistance among treated patients within the United Kingdom [10] . The finding suggests a possible protective role of newer treatment regimens, and particularly therapy based on ritonavir-boosted PIs, against emerging resistance, as well as a greater tendency in recent years to test for drug resistance even among patients for whom poor adherence is strongly suspected. This is in line with the observation that the prevalence of resistance decreased progressively with increasing viral loads to 110,000 copies/mL, which is likely to reflect suboptimal adherence, although our study lacked formally collected adherence data.
Mutations that occurred most commonly at viral loads of !1000 copies/mL included the reverse-transcriptase mutations K65R and M184V and thymidine analogue mutations for the NRTIs; K103N, V108I, Y181C, and G190A for the NNRTIs; and D30N, M46I, V82A, I84V, and L90M for the PIs. The higher frequency of thymidine analogue mutations at viral loads of 11000 copies/mL may be expected, because thymidine analogue mutations will accumulate with prolonged virological failure. However, it is unclear why this observation was seen for the thymidine analogue mutation 1 pathway (M41L, L210W, and T215Y) rather than for the thymidine analogue mutation 2 pathway. We were unable to infer from this analysis whether the presence of resistance mutations at low-level viremia should be interpreted as the early emergence of these mutations within the quasispecies or as a possible effect on viral load of reduced viral fitness. Whereas reductions in fitness have been reported for several NRTI resistance mutations, including K65R and M184V [11] , it should be noted that NNRTI resistance mutations such as K103N do not appear to diminish viral fitness. Overall, the finding of major resistance mutations supports the practice of HIV-1 genotyping among patients with low-level viremia to guide the choice of an effective alternative regimen. It should be noted that the clinical impact of the major mutations that are identified may vary among patients with low viral load according to adherence and other drugs in the regimen [12] . Several limitations of this study should be noted. First, there is potential sampling bias in that some clinical centers do not perform HIV-1 genotyping routinely among patients with detectable viral loads of !1000 copies/mL. Second, the retrospective nature of this analysis means that we were unable to link evolution of mutations within an individual to a particular line of treatment or to inform precisely on the viral load threshold at which mutations may emerge, although this threshold appears to be low. Finally, there may be technical limitations in terms of reliability of resistance testing at very low levels of viremia. However, assay reproducibility has been demonstrated elsewhere [4, 13] .
In summary, our data indicate that although overall rates of drug resistance are decreasing among treatment-experienced patients, HIV-1 genotypic resistance testing among patients with viral loads of !1000 copies/mL did not statistically significantly reduce the likelihood of detecting resistance, compared with testing at higher levels of viremia. Although data do not yet exist regarding the utility of HIV-1 genotyping at low viral load in terms of clinical outcomes, guidelines exist that recommend prompt switching among patients with detectable viremia. The use of HIV-1 genotypic resistance testing among patients with low viral loads may be helpful in clinical practice to allow a timely and optimized therapeutic change and may improve outcomes.
